Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
Latest Information Update: 07 Nov 2021
At a glance
- Drugs GALE 301 (Primary) ; GALE 302 (Primary) ; Sargramostim
- Indications Breast cancer; Male breast cancer; Ovarian cancer
- Focus Therapeutic Use
- Sponsors Galena Biopharma
- 09 Mar 2017 Status changed from active, no longer recruiting to completed, as reported in a Galena Biopharma media release.
- 12 Dec 2016 According to a Galena Biopharma media release, data from this study were presented as a poster at the San Antonio Breast Cancer Symposium (SABCS).
- 12 Dec 2016 Results published in the Galena Biopharma Media Release.